OSE2101 + Pembrolizumab 25 MG/ML [Keytruda]
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-sensitive Ovarian Cancer
Conditions
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
Trial Timeline
Aug 5, 2021 → Dec 1, 2025
NCT ID
NCT04713514About OSE2101 + Pembrolizumab 25 MG/ML [Keytruda]
OSE2101 + Pembrolizumab 25 MG/ML [Keytruda] is a phase 2 stage product being developed by Merck for Platinum-sensitive Ovarian Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04713514. Target conditions include Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04713514 | Phase 2 | Active |
Competing Products
4 competing products in Platinum-sensitive Ovarian Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Farletuzumab + Placebo | Eisai | Phase 2 | 52 |
| Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| AK112 low dose + Chemotherapy + Olaparib + AK112 high dose | Akeso | Phase 2 | 51 |
| ZL-2306(nirapairb) + Placebos | Zai Lab | Phase 3 | 72 |